Prof. Ikuo Kashiwakura

Currently, Professor Kashiwagura is working on the development of effective radiation countermeasures using domestically approved pharmaceutical drugs in mouse models and a new biological dosimetry method to replace chromosome aberration analysis. Among the approved drugs reviewed, the thrombopoietin receptor agonist Romiplostim (RP) was found to have a significant radiation injury-reduction effect, and RP was granted a Japanese patent as a radiation injury-reduction drug (registration date: June 2, 2017, No. 6150374). He has served as a research fellow of the Japan Society for the Promotion of Science (Research Center for Science Systems, 2009-2011), contributing to the development of a grant for scientific research. He served as the Executive Director of research at Hirosaki University for two years starting in 2014, and starting in 2016, he promoted education and research on radiation emergency medicine at Hirosaki University as Vice President. At present, as a special assistant to the president of Hirosaki University, he is leading radiation emergency medicine-related projects underway at the university.